(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 28.1MM | -15% |
Operating Income | -3.4MM | -209% |
Operating Expenses | 31.5MM | - |
Net Income | 18.2MM | -277% |
R&D | 5.5MM | -1% |
G&A | 16MM | +9% |
Interest Expense | 131K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $68.64, indicating a -0.88% shift from the previous trading day.
Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $73.11, indicating a +1.25% shift from the previous trading day.
According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.77, marking a +1.79% move from the previous day.
Ligand (LGND) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
SAN DIEGO, March 05, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.
SAN DIEGO, March 04, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024.
According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?